web analytics
4 C
Munich
Monday, December 5, 2022

Therapeutic Solutions International Inc (OTCMKTS: TSOI) Big Lift on Landmark Patent for Stimulating the Immune System (QuadraMune)

Therapeutic Solutions International Inc (OTCMKTS: TSOI) was up over 130% on Tuesday on $3.7 million in dollar volume after the Company reported it has been awarded a landmark patent for cancer and COVID-19 treatment from the United States Patent and Trademark Office regarding its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase.” To the knowledge of the Company, this is the first issuance of a patent on a nutraceutical supplement for stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the IDO pathway. The supplement, termed “QuadraMune®” is commercially available on the Company website and through Amazon. 

TSOI first got into the covid game back on June 22, 2020 after quietly announced the filing of a patent application covering QuadraMune™. Since than the Company has made serious headway in the space with the stock trading as high as $0.175. Currently on the move northbound TSOI investors are looking for a break over previous highs for confirmation of the next leg up. Microcapdaily first reported on TSOI on June 22, 2020 when the stock was trading for well under the $0.01 mark. Numerous drugs such as Optivo®, Yervoy®, and Keytruda®, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms. This class of drugs, called “checkpoint inhibitors” represent a 15.2 billion dollar a year market. 

Therapeutic Solutions International Inc (OTCMKTS: TSOI) is focused on immune modulation for the treatment of several specific diseases. The Company is focused on three different areas within the same market. They are outlined as follows: 1. Nutraceutical Products – TSI has been producing very high-quality nutraceuticals. Its product, NanoStilbene™ is a nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200mg/ml. 2. StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein-based vaccines. 3. The Jadi Cell product, which belongs to the mesenchymal stem cell (MSC) family of cells, is a unique adult stem cell, which produces higher levels of therapeutic factors compared to other stem cells.  The cells have demonstrated safety in animal models and pilot human trials. 

In October the Company reported the initiation of pilot batch production of JadiCells, its umbilical cord stem cell product cleared by the FDA to enter Phase III clinical trials for COVID-19.  Company scientists have successfully reproduced manufacturing protocols described in the issued US patent # 9,803,176 B2 which is exclusively licensed for pulmonary indications, chronic traumatic encephalopathy, and traumatic brain injury.  Additionally, the Company has filed an extensive patent covering novel manufacturing procedures as well as “second generation” JadiCells. 

https://twitter.com/kapital_gainz/status/1475900144222670851

To Find out the inside Scoop on TSOI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

TSOI

Microcapdaily first reported on TSOI on June 22, 2020 when the stock was trading below the $0.01 mark. Later we stated on TSOI: “Therapeutic Solutions International (OTCMKTS: TSOI) has been on a tear after the FDA gave it the go ahead to start its pivotal Phase 3 trial for COVID-associated lung failure using its JadiCell universal donor stem cell treatment.  Since that kickoff announcement it has been a news bonanza that keeps building on the story.  They are also planning on filing an EUA which is a very bold initiative given the past failures of other COVID-19 companies like CytoDyn Inc. (OTCMKTS: CYDY) which appears to have a drug that works but was denied due to their lack of data.  The treatment is called Jadi Cell and they had excellent clinical trial data supporting their EUA application.  In a randomized controlled clinical trial the JadiCell treatment showed 100% effectiveness in saving COVID-19 ICU patients under age 85. This was the rationale for the application.

TSOI was up over 130% on Tuesday on $3.7 million in dollar volume after the Company reported it has been awarded a landmark patent for cancer and COVID-19 treatment from the United States Patent and Trademark Office regarding its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase.” To the knowledge of the Company, this is the first issuance of a patent on a nutraceutical supplement for stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the IDO pathway. The supplement, termed “QuadraMune®” is commercially available on the Company website and through Amazon. 

In 2013 and subsequently in 2018, Dr. Ichim and colleagues published regression of breast cancer by inhibiting the IDO pathway using an RNA interference approach. The current data and patent granted are representation of years of basic scientific investigation on the relationship between IDO and the immune system. 

TSOI President and CEO, Timothy Dixon had this to say: “The acceptance of our data by the United States Patent Office in granting of the current patent is a major accomplishment for the Company. The Company has numerous patent applications filed covering multiple nutraceuticals and uses including; a) published patent application #16/866430 entitled ‘Nutraceuticals for the Prevention, Inhibition, and Treatment of SARS-Cov-2 and Associated COVID-19’, b) #16/898472 entitled ‘Nutraceuticals for Reducing Myeloid Suppressor Cells’ and c) #16/907335 entitled ‘Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity’.” 

 We have a Monster Pick Coming. Subscribe Right Now!

TSOI was up over 130% on Tuesday on $3.7 million in dollar volume after the Company reported it has been awarded a landmark patent for cancer and COVID-19 treatment from the United States Patent and Trademark Office regarding its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase.” To the knowledge of the Company, this is the first issuance of a patent on a nutraceutical supplement for stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the IDO pathway. The supplement, termed “QuadraMune®” is commercially available on the Company website and through Amazon. TSOI first got into the covid game back on June 22, 2020 after quietly announced the filing of a patent application covering QuadraMune™. Since than the Company has made serious headway in the space with the stock trading as high as $0.175. Currently on the move northbound TSOI investors are looking for a break over previous highs for confirmation of the next leg up. Microcapdaily first reported on TSOI on June 22, 2020 when the stock was trading for well under the $0.01 mark. Numerous drugs such as Optivo®, Yervoy®, and Keytruda®, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms. This class of drugs, called “checkpoint inhibitors” represent a 15.2 billion dollar a year market. We will be updating on TSOI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with TSOI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TSOI either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.